2023年1月5日

100 B系列扩展融资共同通过新生控股/ S, Catalio资本管理和共生,与新的和现有投资者的参与,包括跳跃由拜耳和现代化,以及初始系列B导致烤瓷健康科学,Farallon Capital管理、现金和全球领先的投资公司扩展跑道凝固Metagenomi下一代基因编辑领域中的领导地位,使Metagenomi进步的主要治疗方案临床研究,基因药物和扩张的管道,由最大的专有下一代基因编辑平台Ray Camahort博士新生企业的合伙人Novo控股的全资子公司,以观察员身份加入Metagenomi董事会05年1月,2023年是东部标准时间07:00维尔,加州——(业务线)——Metagenomi,基因药物公司全资的多功能组合,下一代基因编辑系统,今天宣布的一系列B扩展融资,共同通过新生控股/ S, Catalio资本管理和共生,新的和现有投资者的参与。本系列100美元融资带来的总收益275美元,超过30投资集团参与。与融资,Ray Camahort博士新生企业的合伙人将加入Metagenomi董事会作为观察员。“在Novo控股,我们的目的是改善人们的健康和社会的可持续发展和地球。Metagenomi继续显示一个令人印象深刻的记录快速发展的新型基因编辑系统和推进他们通过临床验证,”雷说Camahort博士新生企业的合伙人。Metagenomi”相结合的新一代技术平台,临床进展,大量验证和强劲的投资者合作,我们相信该公司将迅速开发疗法治疗范围广泛的遗传疾病。”,一个健康的现金跑道的高跟鞋与现代化和Ionis制药成功的伙伴关系,这些额外的资金将使Metagenomi推进通过临床前开发和临床治疗计划的铅概念证明。此外,该公司计划提名其专有的基因药物管道额外的治疗目标,得益于其自动发现引擎和多功能基因编辑工具箱,扩展到额外的临床前概念验证研究。“关闭本系列的B扩展融资证明了我们的重大进展在过去的一年。我们进一步扩大全资的工具箱,下一代基因编辑技术,开始了我们的第一个非人类灵长类动物(额定马力)体内基因编辑概念验证研究和加强我们的战略业务发展联盟,”布莱恩·c·托马斯说,Metagenomi的创始人和CEO。“这额外的资本为我们提供了最初的临床里程碑的可见性以及扩大体内基因编辑应用程序的管道。” About Metagenomi Metagenomi is a gene editing company committed to developing potentially curative therapeutics by leveraging a proprietary toolbox of next-generation gene editing systems to accurately edit DNA where current technologies cannot. Our metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. We adapt and forge these naturally evolved systems into powerful gene editing systems that are ultra-small, extremely efficient, highly specific and have a decreased risk of immune response. These systems fuel our pipeline of novel medicines. Our goal is to revolutionize gene editing for the benefit of patients around the world. For more information, please visit https://metagenomi.co About Novo Holdings Novo Holdings is a holding and investment company that is responsible for managing the assets of the Novo Nordisk Foundation, one of the world’s largest enterprise foundations. The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation. Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk and Novozymes (the Novo Group companies) and manages an investment portfolio, with a long-term return perspective. Novo Holdings invests in life science companies of all stages of development and also manages a broad portfolio of equities, bonds, real estate and infrastructure assets as well as private equity investments. As of year-end 2021, Novo Holdings had total assets of USD 106 billion.